Solid Biosciences up 10% following J.P. Morgan upgrade
J.P. Morgan upgraded Solid Biosciences from neutral to outperform. Firm also raised its price target to $15 from $10. Firm believes label expansion for Duchenne muscular dystrophy treatment bodes well for Solid's own candidate, SGT-003.
Seeking Alpha · 2h ago
Look Under The Hood: FXH Has 16% Upside
NASDAQ · 8h ago
Weekly Report: what happened at SRPT last week (0708-0712)?
Weekly Report · 11h ago
Notable ETF Inflow Detected - XBI, SRPT, UTHR, ALNY
NASDAQ · 4d ago
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
NASDAQ · 07/08 16:04
Weekly Report: what happened at SRPT last week (0701-0705)?
Weekly Report · 07/08 09:20
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Sarepta Therapeutics received a full approval for its gene therapy for Duchenne muscular dystrophy on June 20. The company's stock is up on the news, but the company's future is still uncertain. The FDA's approval of Elevidys may not be as clear-cut as it appears.
The Motley Fool · 07/06 12:00
Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Sarepta Therapeutics' price-to-sales ratio of 10.3x is within range of the industry median. The stock is up 39% in the last year. The company's revenue has been rising slower than most other companies. The P/S is a good barometer of revenue expectations for the company.
Simply Wall St · 07/05 10:15
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Sarepta Therapeutics has outperformed the market over the past 10 years by 8.61% on an annualized basis. The company has an average annual return of 19.45%. If an investor bought $100 of SRPT stock 10 years ago, it would be worth $596.22 today.
Benzinga · 07/04 14:30
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
Sarepta Therapeutics' stock is up 60% since the FDA granted accelerated approval for its gene therapy treatment for Duchenne muscular dystrophy. The label expansion paves the way for much more revenue growth for the company. The company has more than 40 programs in its pipeline.
The Motley Fool · 07/04 10:35
1 Soaring Growth Stock to Buy and Hold for 10 Years
Sarepta Therapeutics' shares are up by 62% year to date. The biotech's most important drug, Elevidys, was approved for Duchenne muscular dystrophy in June. Sarepta is a highly innovative company with a strong pipeline. The stock looks like a good pick to hold onto over the next decade.
The Motley Fool · 07/03 14:05
Best Momentum Stocks to Buy for July 3rd
NASDAQ · 07/03 14:00
New Strong Buy Stocks for July 3rd
NASDAQ · 07/03 10:49
Sarepta Therapeutics Price Target Maintained With a $205.00/Share by Piper Sandler
Dow Jones · 07/01 14:04
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 07/01 14:04
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
Sarepta Therapeutics is a biotechnology company focused on treating rare diseases. 25 analysts have provided ratings for SareptaTherapeutics in the past three months. The company has an average price target of $182.8, with a high estimate of $235.00. The average 12-month price target surpasses the previous average of $165.61.
Benzinga · 07/01 14:01
Validea Detailed Fundamental Analysis - SRPT
NASDAQ · 07/01 13:38
Sarepta Therapeutics (SRPT) Gets a Buy from Piper Sandler
TipRanks · 07/01 10:36
Weekly Report: what happened at SRPT last week (0624-0628)?
Weekly Report · 07/01 09:20
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. Granted equity awards on June 28, 2024 to 23 individuals hired by the company in June 2024. The employees received options to purchase 5,100 shares of Sarepta's common stock and 19,980 restricted stock units. The company is the leader in precision genetic medicine for rare diseases.
Barchart · 06/28 17:30
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.